Skip to search formSkip to main contentSkip to account menu

sofosbuvir / velpatasvir

Known as: SOFOSBUVIR/VELPATASVIR 
National Institutes of Health

Related topics

Related topics

2 relations
sofosbuvirvelpatasvir

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Real-world Effectiveness of Sofosbuvir/Velpatasvir for Treatment of Chronic Hepatitis C in British Columbia, Canada: A Population-Based Cohort Study
Abstract Background Clinical trials show high efficacy of sofosbuvir/velpatasvir (SOF/VEL), but there are limited data from “real… 
2020
2020
Modeling-based response-guided therapy for chronic hepatitis C under glecaprevir/pibrentasvir may identify patients for ultra-short treatment duration.
We recently showed in a proof-of-concept study that real-time modeling-based response-guided therapy (RGT) can shorten hepatitis… 
2019
2019
Cell Culture Studies of the Efficacy and Barrier to Resistance of Sofosbuvir-Velpatasvir and Glecaprevir-Pibrentasvir against Hepatitis C Virus Genotypes 2a, 2b, and 2c
The introduction of highly efficient therapies with direct-acting antivirals (DAA) for patients with chronic hepatitis C virus… 
2019
2019
Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany
Background Newer direct-acting antiviral therapies are increasingly becoming the therapy of choice in patients with hepatitis C… 
2019
2019
Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort
Treatment guidelines differ in their recommendation to determine baseline resistance associated substitutions (RAS) before… 
2019
2019
Transjugular Intrahepatic Portosystemic Shunt: A Possible Risk Factor for Direct‐Acting Antiviral Treatment Failure in Patients With Hepatitis C?
Direct‐acting antiviral (DAA) therapies have revolutionized the treatment of chronic hepatitis C virus infection, achieving… 
2018
2018
Sofosbuvir and velpatasvir with or without voxilaprevir in direct‐acting antiviral‐naïve chronic hepatitis C: patient‐reported outcomes from POLARIS 2 and 3
Chronic hepatitis C infection leads to impairment of patient‐reported outcomes (PROs). Treatment with direct‐acting antiviral… 
2018
2018
IDDF2018-ABS-0112 Safety and efficacy of sofosbuvir/velpatasvir in a genotype 1–6 hcv infected population from singapore, malaysia, thailand, and vietnam: results from a phase 3, clinical trial
Background The prevalence of hepatitis C virus (HCV) in Singapore, Malaysia, Thailand, and Vietnam, ranges from 1%–3%. Because of… 
Review
2017
Review
2017
Sofosbuvir/velpatasvir fixed-dose combination for the treatment of chronic hepatitis C virus infection.
The fixed-dose combination of sofosbuvir, a nucleotide analogue NS5B polymerase inhibitor, and velpatasvir, a second-generation… 
2016
2016
Antiretroviral Use in the CEASE Cohort Study and Implications for Direct-Acting Antiviral Therapy in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection
Potential drug-drug interactions are expected and will impact on DAA prescribing in HIV/HCV co-infection. An adequate evaluation… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)